These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 21649506

  • 21. DNA vaccine encoding HPV-16 E7 with mutation in L-Y-C-Y-E pRb-binding motif induces potent anti-tumor responses in mice.
    Bahrami AA, Ghaemi A, Tabarraei A, Sajadian A, Gorji A, Soleimanjahi H.
    J Virol Methods; 2014 Sep; 206():12-8. PubMed ID: 24880067
    [Abstract] [Full Text] [Related]

  • 22. A novel fusion protein-based vaccine comprising a cell penetrating and immunostimulatory peptide linked to human papillomavirus (HPV) type 16 E7 antigen generates potent immunologic and anti-tumor responses in mice.
    Granadillo M, Vallespi MG, Batte A, Mendoza O, Soria Y, Lugo VM, Torrens I.
    Vaccine; 2011 Jan 29; 29(5):920-30. PubMed ID: 21145912
    [Abstract] [Full Text] [Related]

  • 23. HSP70 modified response against HPV based tumor.
    Farzanehpour M, Soleimanjahi H, Hassan ZM, Amanzadeh A, Ghaemi A, Fazeli M.
    Eur Rev Med Pharmacol Sci; 2013 Jan 29; 17(2):228-34. PubMed ID: 23377813
    [Abstract] [Full Text] [Related]

  • 24. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.
    Chen CH, Wang TL, Ji H, Hung CF, Pardoll DM, Cheng WF, Ling M, Wu TC.
    Gene Ther; 2001 Jan 29; 8(2):128-38. PubMed ID: 11313782
    [Abstract] [Full Text] [Related]

  • 25. A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle.
    Lin F, Shen X, McCoy JR, Mendoza JM, Yan J, Kemmerrer SV, Khan AS, Weiner DB, Broderick KE, Sardesai NY.
    Vaccine; 2011 Sep 09; 29(39):6771-80. PubMed ID: 21199706
    [Abstract] [Full Text] [Related]

  • 26. Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors.
    Diniz MO, Cariri FA, Aps LR, Ferreira LC.
    Hum Gene Ther; 2013 Oct 09; 24(10):861-70. PubMed ID: 24007495
    [Abstract] [Full Text] [Related]

  • 27. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ.
    Clin Cancer Res; 2008 Jan 01; 14(1):169-77. PubMed ID: 18172268
    [Abstract] [Full Text] [Related]

  • 28. Combined immunization with DNA and transduced tumor cells expressing mouse GM-CSF or IL-2.
    Rittich S, Duskova M, Mackova J, Pokorna D, Jinoch P, Smahel M.
    Oncol Rep; 2005 Feb 01; 13(2):311-7. PubMed ID: 15643517
    [Abstract] [Full Text] [Related]

  • 29. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
    Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI.
    Cancer Res; 2002 Dec 15; 62(24):7234-40. PubMed ID: 12499264
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Recombinant Leishmania tarentolae encoding the HPV type 16 E7 gene in tumor mice model.
    Salehi M, Taheri T, Mohit E, Zahedifard F, Seyed N, Taslimi Y, Sattari M, Bolhassani A, Rafati S.
    Immunotherapy; 2012 Nov 15; 4(11):1107-20. PubMed ID: 23194361
    [Abstract] [Full Text] [Related]

  • 32. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice.
    Eiben GL, Velders MP, Schreiber H, Cassetti MC, Pullen JK, Smith LR, Kast WM.
    Cancer Res; 2002 Oct 15; 62(20):5792-9. PubMed ID: 12384540
    [Abstract] [Full Text] [Related]

  • 33. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity.
    Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z, Kurman RJ, Pardoll DM, Wu TC.
    Gene Ther; 2000 May 15; 7(9):726-33. PubMed ID: 10822298
    [Abstract] [Full Text] [Related]

  • 34. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 35. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
    Jin HS, Park EK, Lee JM, NamKoong SE, Kim DG, Lee YJ, Jun HJ, Han BD, Bae SM, Ahn WS.
    Gynecol Oncol; 2005 May 01; 97(2):559-67. PubMed ID: 15863160
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Antitumor therapeutic effects of e7 subunit and DNA vaccines in an animal cervical cancer model: antitumor efficacy of e7 therapeutic vaccines is dependent on tumor sizes, vaccine doses, and vaccine delivery routes.
    Sin JI, Hong SH, Park YJ, Park JB, Choi YS, Kim MS.
    DNA Cell Biol; 2006 May 01; 25(5):277-86. PubMed ID: 16716117
    [Abstract] [Full Text] [Related]

  • 38. Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1.
    Song MY, Park SH, Nam HJ, Choi DH, Sung YC.
    J Immunother; 2011 Apr 01; 34(3):297-306. PubMed ID: 21389868
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.